Diabetic nephropathy: Focus on current and future therapeutic strategies

Current Drug Metabolism

Volumn 17, Issue 5, 2016, Pages 497-502

  Pofi, Riccardo ^a   Di Mario, Francesca ^a   Gigante, Antonietta ^a   Rosato, Edoardo ^a   Isidori, Andrea M ^a   Amoroso, Antonio ^a   Cianci, Rosario ^a   Barbano, Biagio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic kidney disease; Diabetes mellitus; Diabetic nephropathy; End stage renal disease; Novel therapies

Indexed keywords

BARDOXOLONE METHYL; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; PERFINIDONE; PYRIDOXAMINE; RUBOXISTAURIN; SILYMARIN; UNCLASSIFIED DRUG; VITAMIN; VITAMIN D; ANTIDIABETIC AGENT;

ANAMNESIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COMPLICATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; GLYCEMIC CONTROL; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; LIFESTYLE MODIFICATION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; DIABETIC NEPHROPATHIES; PATHOPHYSIOLOGY;

DIABETIC NEPHROPATHIES; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84963525897     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021705160324165553     Document Type: Review

References (82)

1. Danaei, G.; Finucane, M. M.; Lu, Y. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systemic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 2011, 31, 1201-1206.
2. Alkins, R. C.; Zimmet, P. Diabetic kidney disease: act now or pay later. Kidney Int., 2010, 77, 375-577.
3. Akmal, M. Hemodialysis in diabetic patients. Am. J. Kidney Dis., 2001;38, S195-S199.
4. Groop, P. H.; Thomas M. C.; Moran J. L. The presence and severity of chronic kidney disease predicts all - cause mortality in type 1 diabetes. Diabetes, 2009, 58, 1651-1658.
5. Afkarian, M.; Sachs, M. C.; Kestenbaum, B. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol., 2013, 24, 302-308.
6. Mogensen, C. Glomerular hyperfiltration in human diabetes. Diabetes Care, 1994, 17, 770-775.
7. Mogensen, C. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia, 1999, 42, 263-285.
8. Caramori, M. L.; Fioretto, P.; Mauer, T. The need of early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes, 2008, 49, 1399-408.
9. Karalliedde, J.; Viberti, G. Microalbuminuria and cardiovascular risk. Am. J. Hypertens., 2004, 17, 986-993.
10. Standards of medical care in diabetes - 2015: summary of revisions. Diabetes Care, 2015;38(Suppl S4) doi: 10.2337/dc15-S003.
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N. Engl. J. Med., 1993, 329, 977-986.
12. Holman, R. R.; Paul, S. K.; Bethel, M. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 2008, 359, 1577-1589.
13. Perkovic, V.; Heerspink, H. L.; Chalmers J. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int., 2013, 83, 517-523.
14. Gerstein, H. C.; Miller, M. E.; Byington, R. P. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358, 2545-2559.
15. Bakris, G. L.; Ruilope, L. M.; McMorn, S. O. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J. Hypertens., 2006, 24, 2047-2055.
16. Nakamura, T.; Ushiyama, C.; Shimada, N. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J. Diabetes Complications, 2000, 14, 250-254.
17. Sarafidis, P. A.; Stafylas, P. C.; Georgianos, P. I. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a metaanalysis. Am. J. Kidney Dis., 2010, 55, 835-847.
18. Nissen, S. E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356, 2457-2471.
19. Hattori, S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J., 2011, 58, 69-73.
20. Sakata, K.; Hayakawa, M.; Yano, Y. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab. Res. Rev., 2013, 29, 624-630.
21. Schernthaner, G.; Mogensen, C. E.; Schernthaner, G. H. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab. Vasc. Dis. Res., 2014, 11(5), 306-323.
22. Liu, X. Y.; Zhang, N.; Chen, R.; Zhao, J. G.; Yu, P. Efficacy and safety of sodium glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J. Diabetes Complications, 2015, 29(8), 1295-1230.
23. De Nicola, L.; Gabbai, F. B.; Liberti, M. E.; Sagliocca, A.; Conte, G.; Minutolo, R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: Targeting the renal tubule in diabetes. Am. J. Kidney Dis., 2014, 64(1), 16-24.
24. Ranadive, S. A.; Chen, A. X.; Serajuddin, A. T. Relative lipophilicities and structuralpharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res., 1992, 9, 1480-1486.
25. Burnier, M.; Brunner, H. R. Angiotensin II receptor antagonists. Lancet, 2000, 355, 637-645.
26. Adler, A. I.; Stratton, I. M.; Neil, H. A. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 2000, 321, 412-419.
27. Bakris, G. L.; Weir, M. R.; Shanifar, S. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med., 2003, 163, 1555-1565.
28. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am. J. Kidney Dis., 2012, 60, 850-886.
29. Viberti, G.; Wheeldon, N. M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressureindependent effect. Circulation, 2002, 106, 672-678.
30. De Galan, B. E.; Zoungas, S.; Chalmers, J. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2009, 52, 2328-2336.
31. Ruggenenti, P.; Fassi, A.; Ilieva, A. P. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med., 2004, 351, 1941-1951.
32. Lewis, E. J.; Hunsicker, L. G.; Clarke, W. R. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-860.
33. Brenner, B. M.; Cooper, M. E.; de Zeeuw, D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
34. Barnett, A. H.; Bain, S. C.; Bouter, P. Angiotensin-receptor blockade versus convertingenzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med., 2004, 351, 1952-1961.
35. Mann, J. F.; Anderson, C.; Gao, P. Dual inhibition of the reninangiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J. Hypertens., 2013, 31, 414-421.
36. Fried, L. F.; Emanuele, N.; Zhang, J. H. Combined angiotensin inhibition in diabetic nephropathy. N. Engl. J. Med., 2014, 370(8), 779.
37. Parving, H. H.; Brenner, B. M.; McMurray, J. J. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med., 2012, 367, 2204-2213.
38. Schjoedt, KJ; Rossing, K.; Juhl, T. R. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int., 2006, 70, 536-542.
39. Epstein, M.; Williams, G. H; Weinberger, M. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol., 2006, 1, 940-951.
40. Brenner, B. M.; Cooper, M. E.; De Zeeuw, D. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
41. Lewis, EJ.; Hunsicker, L. G.; Bain, R. P. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med., 1993, 329, 1456-1462.
42. Lewis, EJ; Hunsicker, L. G; Clarke, W. R. Collaborative Study Group: Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-860.
43. Voziyan, P. A.; Hudson, B. G.; Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann. NY. Acad. Sci., 2005, 1043, 807-816.
44. Genuth, S.; Sun, W.; Cleary, P. DCCTySkin Collagen Ancillary Study Group: Glycation and carboxy-methyl-lysine levels in skin 27 collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes, 2005, 54, 3103-3111.
45. Mark, E. W.; Bolton W. K., Raja, G. K. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol, 2007, 27, 605-614.
46. Lewis, EJ.; Greene, T.; Spitalewiz, S. Pyridorin in type 2 diabetic nephropathy. J. Am. Nephrol, 2012, 23, 131-136.
47. Dwyer, P. J.; Greco, B. A.; Umanath, K. Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): Lessons learned from a pilot study. Nephron, 2015, 129, 22-28.
48. Sanz, A. B.; Sanchez-Nino, M. D.; Ramos, A. M. NF-kappaB in renal inflammation. J. Am. Soc. Nephrol, 2010, 21, 1254-1262.
49. Ruiz, S.; Pergola, P. E.; Zager, R. A. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int., 2013, 83, 1029-1041.
50. Pergola, P. E.; Krauth, M.; Huff, J. W. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am. J. Nephrol, 2011, 33, 469-476.
51. Pergola, P. E.; Raskin, P.; Toto, R. D. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med., 2011, 365, 327-336.
52. de Zeeuw, D.; Akizawa, T.; Audhya, P. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med., 2013, 369, 2492-2503.
53. Zhang, Z.; Zhang, Y.; Ning, G. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc. Natl. Acad. Sci. USA, 2008, 105(41), 15896-15901.
54. Wang, Y.; Deb, D. K.; Zhang, Z. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J. Am. Soc. Nephrol, 2012, 23(12), 1977-1986.
55. Zhang, Z.; Sun, L.; Wang, Y. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int., 2008, 73, 163-171.
56. De Zeeuw, D.; Agarwal, R.; Amdahl, M. Selective vitamin D receptor ac-tivation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, 2010, 376, 1543-1551.
57. Yan, C. L. Podocytes as Target of Vitamin D. Curr. Diabetes Rev., 2011, 7, 35-40.
58. Nakai, K.; Fujii, H.; Kono, K. Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. Am. J. Hypertens., 2014, 27(4), 586-595.
59. Meier, M.; Menne, J.; Park, J. K. Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J. Am. Soc. Nephrol, 2007, 18, 1190-1198.
60. Menne, J.; Meier, M.; Park, J. K. Inhibition of protein kinase C in diabetic nephropathy - where do we stand? Nephrol. Dial. Transplant., 2009, 24, 2021-2023.
61. Menne, J.; Shushakova, N.; Bartels, J. Dual inhibition of classical protein kinase C-alpha and protein kinase C-beta isoforms protects against experimental murine diabetic nephropathy. Diabetes, 2013, 62, 1167-1174.
62. Tuttle, K. R.; Bakris, G. L.; Toto, R. D. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care, 2005, 28, 2686-2690.
63. Tuttle, K. R.; McGill, J. B.; Haney, DJ. Kidney outcomes in longterm studies of ruboxistaurin for diabetic eye disease. Clin. J. Am. Soc. Nephrol, 2007, 2, 631-636.
64. Garud, M. S.; Kulkarni, Y. A. Hyperglycemia to nephropathy via transforming growth factor beta. Curr. Diabetes Rev., 2014, 10(3), 182-189.
65. Meng, L. V.; Chen, Z.; Hu, G. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov. Today, 2015, 332-346.
66. Sharma, K.; Ix, J. H.; Mathew, A. V. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol., 2011, 22(6), 1144-1151.
67. Soma, J.; Sato, K. Effect of tranilast in early-stage diabetic nephropathy. Nephrol. Dial. Transplant., 2006, 21(10), 2795-2799.
68. Adler, S. G.; Schwartz, S.; Williams, M. E. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol, 2010, 5, 1420-1428.
69. De Sanctis, M. I.; Cesarone, M. R.; Belcaro, G. Treatment of intermittent claudication with pentoxifylline: A 12-month, randomized trial. Walking distance and microcirculation. Angiology, 2002, 53(Suppl 1), S7-S12.
70. McCormick, B. B.; Sydor, A.; Akbari, A. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am. J. Kidney Dis., 2008, 52(3), 454-463.
71. Han, S. J.; Kim, H. J.; Kim, DJ. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetol. Metab. Syndr., 2015, 7, 64.
72. Navarro-González, J. F.; Mora-Fernández, C; Muros de Fuentes, M. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial. J. Am. Soc. Nephrol, 2015, 26(1), 220-229.
73. Fallahzadeh, M. K.; Dormanesh, M.; Mahdi Sagheb, M. Effect of addition of silymarin to renin - angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: A randomized, double-blind, placebo-controlled trial. Am. J. Kidney Dis., 2012, 60(6), 896-903.
74. Kohan, D. E.; Pollock, D. M. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br. J. Clin. Pharmacol., 2013, 76(4), 573-579.
75. Neuhofer, W.; Pittrow, D. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur. J. Clin. Invest., 2009, 39(Suppl 2), 50-67.
76. Saleh, M. A.; Boesen, E. I.; Pollock, J. S. Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia, 2011, 54(4), 979-988.
77. Cai, L.; Chen, S.; Evans, T. Endothelin-1-mediated alteration of metallothionein and trace metals in the liver and kidneys of chronically diabetic rats. Int. J. Exp. Diabetes Res., 2002, 3(3), 193-198.
78. Wenzel, R. R.; Littke, T. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol, 2009, 20, 655-664.
79. Mann, J. F.; Green, D. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol, 2010, 21, 527-535.
80. De Zeeuw, D.; Coll, B.; Andress, D. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol, 2014, 25(5), 1083-1093.
81. Yuan, W.; Li, Y.; Wang, J. Endothelin receptor antagonists for diabetic nephropathy: A meta analysis. Nephrology, 2015, 20, 459-466.
82. Khajehdehi, P.; Pakfetrat, M.; Javidnia, K. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-P and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand. J. Urol. Nephrol., 2011, 45(5), 365-370.